UBS Microcap Fund is an Managed Funds investment product that is benchmarked against ASX Index Small Ordinaries Index and sits inside the Domestic Equity - Small Cap Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The UBS Microcap Fund has Assets Under Management of 35.17 M with a management fee of 1.2%, a performance fee of 20.00% and a buy/sell spread fee of 0.7%.
After fees and expenses, the Portfolio increased by 1.70% during the month, outperforming its benchmark by 301 bps.
The largest positive contributors were Botanix Pharmaceuticals, Energy One and Laserbond. Botanix Pharmaceuticals traded higher as the targeted FDA approval date for their novel drug Sofpironium Bromide was reaffirmed for end of September 2023. Energy One received a non-binding indicative offer for their business at $5.85/share being a 44% premium to its last traded price. Laserbond provided a strong FY23 result with revenue up 25.7% on pcp and net profit after tax up 31.1%.
The largest negative contributors were NextEd, XRF Scientific and PeopleIn. Tertiary education provider NextEd traded lower following a trading update highlighting the negative implications of the temporary COVID-19, 408 Visa on their business which has since ceased. XRF scientific traded lower after reaching all time highs. PeopleIn was sold off after missing their pre-announced EBITDA guidance range of $62m-$66m for FY23, generating $60.9m.
Product Snapshot
Performance Review
Product Overview
Peer Comparison
Product Details